Machine Learning Identifies TM4SF1 as Key Driver of Lung Adenocarcinoma

Bioengineer.org

Source published: Site published:

Original article · فارسی

A study at Guangzhou Women and Children’s Medical Center found that children with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL) lived longer when they received a stem cell transplant after CAR-T cell therapy had put their cancer into remission. Although experimental CAR-T treatments made the leukemia disappear at first in many children, long-lasting remission was uncommon in children whose bone marrow was affected unless they later received a stem cell transplant.

Doctors have long debated whether children who respond well to CAR-T cell treatment still need a stem cell transplant. To study this question, researchers examined patient outcomes using current National Comprehensive Cancer Network guidelines and international standards for measuring treatment responses.

This study looked back at the medical records of 34 children treated at one medical center between June 2018 and December 2023. Each child received an experimental CAR-T cell treatment made from their own cells. The treatments used either CD28 or 4-1BB as a supporting part of the CAR-T cells. Some treatments targeted one marker on cancer cells, while others targeted two. Their goal was to destroy cancerous B cells.

The first treatment results were strong. A total of 26 of the 34 children reached complete remission or complete remission with incomplete recovery of blood cell counts. This was an overall response rate of 76.5 percent. All 26 children who responded had no measurable signs of remaining disease using a sensitive test called minimal residual disease (MRD) testing. Serious immune-related side effects occurred in some patients but were generally manageable. Severe cytokine release syndrome (grade 3 or higher) occurred in 11.8 percent of patients. Grade 3 immune effector cell-associated neurotoxicity syndrome occurred in 2.9 percent.

The researchers followed all 34 children for a median of 21.4 months. Using Kaplan–Meier statistical estimates, they calculated that the overall survival rate at two years was 57.4 percent. The 95 percent confidence interval was 38.8 to 72.3 percent.

The possible benefit of a follow-up stem cell transplant was especially clear among the 24 children who had leukemia in their bone marrow and reached remission with no measurable remaining disease. Of these children, 20 received an allogeneic hematopoietic stem cell transplant, which uses stem cells from a donor. Four did not receive a transplant. The estimated two-year survival rate was 79.3 percent for children who received a transplant, compared with 25.0 percent for those who did not. This difference was statistically significant in a log-rank comparison, with a p-value of 0.006. All four children with bone marrow involvement who did not receive a transplant had their leukemia return and eventually died.

The researchers also used a six-month landmark analysis and a time-dependent Cox analysis to check these findings. In the six-month landmark analysis, which included 21 eligible patients, receiving a stem cell transplant by the six-month point was still linked to better overall survival. The p-value was 0.047.

The researchers also found that CAR-T treatment alone did not always provide lasting control of the disease. When they counted stem cell transplants performed during remission as events that ended follow-up, no patient remained free of an event for more than 12.1 months. This was different from the usual two-year event-free survival estimate of 61.8 percent. However, outcomes varied by where the leukemia had returned. Two of the four children whose leukemia had returned only in the testicles maintained long-lasting remission without a later stem cell transplant. Stem cell transplants used as rescue treatment after the cancer returned following CAR-T treatment also appeared to help a small number of patients.

The authors concluded that CAR-T cell treatment can help many children reach remission with no measurable remaining disease, and that its serious short-term side effects are generally manageable. However, for children with leukemia in their bone marrow, receiving an allogeneic stem cell transplant afterward was strongly linked to longer-lasting control of the disease. The researchers cautioned that their findings came from a small, retrospective study and need to be confirmed in future studies that follow patients prospectively.

Subject of Research: Stem cell transplantation after CAR-T cell therapy in children with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia

Article Title: Impact of consolidative HSCT after CAR T-cell–induced remission in pediatric relapsed/refractory B-ALL: a single-center retrospective cohort

Article References: Liao, Z., Kuang, F., Luo, Y., Wang, J., Hao, W., Zheng, Q., Lin, H., Wang, P., Jiang, H., & Zhang, W. (2026). Impact of consolidative HSCT after CAR T-cell–induced remission in pediatric relapsed/refractory B-ALL: a single-center retrospective cohort. Frontiers in Oncology, 16, Article 1866852. https://doi.org/10.3389/fonc.2026.1866852

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1866852

Keywords: childhood leukemia, B-cell acute lymphoblastic leukemia, CAR-T cell therapy, hematopoietic stem cell transplantation, relapsed or hard-to-treat leukemia, minimal residual disease, complete remission, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, overall survival, event-free survival, landmark analysis, time-dependent Cox regression, CAR-T cells made from the patient's own cells, leukemia involving the bone marrow, isolated testicular relapse, retrospective cohort study